KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average) (2018 - 2026)

Esperion Therapeutics filings provide 8 years of Shares Outstanding (Diluted Average) readings, the most recent being $207.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 11.05% to $207.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $207.9 million, a 11.05% increase, with the full-year FY2025 number at $207.9 million, up 11.05% from a year prior.
  • Shares Outstanding (Diluted Average) hit $207.9 million in Q4 2025 for Esperion Therapeutics, up from $200.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $207.9 million in Q4 2025 to a low of $26.0 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $106.2 million (2023), compared with a mean of $116.5 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): decreased 9.11% in 2021 and later skyrocketed 156.31% in 2022.
  • Esperion Therapeutics' Shares Outstanding (Diluted Average) stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then skyrocketed by 55.26% to $103.1 million in 2023, then soared by 81.54% to $187.2 million in 2024, then grew by 11.05% to $207.9 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $207.9 million (Q4 2025), $200.7 million (Q3 2025), and $197.5 million (Q2 2025) per Business Quant data.